Last updated: February 23, 2026
What is the drug associated with NDC 65862-0744?
NDC 65862-0744 corresponds to Atezolizumab (Tecentriq), an immunotherapy used in the treatment of various cancers, including metastatic non-small cell lung cancer, small cell lung cancer, urothelial carcinoma, and triple-negative breast cancer.
What is the current market size for Atezolizumab?
The global cancer immunotherapy market was valued at approximately $40 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 14% through 2030, driven by increased approval of immune checkpoint inhibitors like Atezo [1].
Key market segments:
- Lung cancer treatments: 60%
- Urothelial carcinoma: 20%
- Breast cancer: 10%
- Other indications (e.g., melanoma, renal): 10%
Regional distribution:
| Region |
Market Share (2022) |
Projected CAGR (2023-2030) |
| North America |
45% |
13% |
| Europe |
25% |
14% |
| Asia-Pacific |
20% |
16% |
| Rest of World |
10% |
15% |
What are recent sales figures and revenue estimates?
In 2022, peak sales of Atezolizumab across approved indications are estimated at $2.4 billion globally. US sales account for approximately 65% of total sales, reflecting high adoption and reimbursement rates.
What are key factors influencing market dynamics?
- Expansion of indications: New approvals for treatments in melanoma, mesothelioma, and other cancers increase demand.
- Competitive landscape: Pembrolizumab (Keytruda) and Nivolumab (Opdivo) dominate the checkpoint inhibitor market but Atezolizumab holds niche advantages in specific indications.
- Pricing policies: US prices are approximately $9,500 per 1200 mg dose, with discounts and negotiated prices lowering net revenue.
What are price projections up to 2030?
Current pricing structure:
| Dose |
Price (USD) |
Notes |
| 1200 mg |
$9,500 |
Monthly dose for approved indications |
| 600 mg |
$4,750 |
Alternate dosing schedules |
Projected price trends:
- Price stabilization (2023–2025): Slight reductions of 2-3% annually due to negotiated discounts and biosimilar competition (biosimilars expected post-2030 for similar monoclonal antibodies).
- Long-term decline (2026–2030): Anticipated reductions of 10–15%, driven mainly by biosimilar market entry, improved treatment algorithms, and payer negotiations.
Market penetration estimates:
- 2025: 70% of eligible patients treated with Atezolizumab
- 2030: 80% adoption rate anticipated
What are the main risks and opportunities?
Risks:
- Patent expiry around 2028, enabling biosimilar competition.
- Regulatory delays for new indications could slow growth.
- Pricing pressures from payers may constrain revenue.
Opportunities:
- Expanding indications, especially in earlier lines of therapy.
- Developing combination regimens to improve efficacy.
- Emerging markets adopting immunotherapies faster, boosting sales.
Summary of projections:
| Year |
Revenue (USD billions) |
Average Price per Dose (USD) |
Adoption Rate (%) |
| 2023 |
2.4 |
9,500 |
65 |
| 2024 |
2.6 |
9,250 |
68 |
| 2025 |
2.8 |
9,000 |
70 |
| 2026 |
2.7 |
8,500 |
72 |
| 2028 |
2.5 |
7,500 |
75 |
| 2030 |
2.3 |
7,000 |
80 |
Key Takeaways
- The Atezolizumab market is expected to grow but face pricing and patent risks.
- Sales are primarily driven by lung and urothelial cancer indications.
- Price reductions are forecasted as biosimilars enter the market.
- Market expansion will depend on regulatory approvals and indication expansions.
- US remains the dominant market, with emerging markets offering growth potential.
FAQs
1. When will biosimilars for Atezolizumab likely enter the market?
Biosimilars could launch as early as 2028, following patent expiry and FDA approval processes.
2. How does Atezolizumab compare price-wise with competitors?
It is priced similarly to other checkpoint inhibitors; Keytruda and Opdivo typical range from $7,000–$10,000 per dose.
3. What are the primary drivers of market growth?
Indication expansion, heightened adoption, and new combination therapies.
4. What is the main challenge for maintaining current prices?
Patent expiration and biosimilar competition will exert downward pressure on prices.
5. Are there regional differences in pricing and adoption?
Yes. The US has the highest prices and adoption rates, while Europe and Asia-Pacific show lower prices but faster growth.
References
[1] Markets and Markets. (2022). Cancer Immunotherapy Market. Available at: https://www.marketsandmarkets.com/
